2021
Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer.
Takvorian S, Parikh R, Vader D, Wileyto E, Clark A, Lee D, Goyal G, Rocque G, Dotan E, Geynisman D, Phull P, Spiess P, Kim R, Davidoff A, Gross C, Miksad R, Calip G, Shulman L, Mamtani R, Hubbard R. Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer. Journal Of Clinical Oncology 2021, 39: 1528-1528. DOI: 10.1200/jco.2021.39.15_suppl.1528.Peer-Reviewed Original ResearchAdvanced solid cancersTreatment initiationAdvanced cancer diagnosisAdvanced cancerSolid cancersCancer typesCox proportional hazards modelCOVID-19 pandemicSystemic therapy initiationSystemic treatment initiationTimely care deliveryDe novo cancerDe novo diseaseAdvanced breast cancerCancer diagnosisLife-prolonging therapiesProportional hazards modelInterrupted time series analysisDe-identified databaseProbability of treatmentNovo diseaseTherapy initiationNovo cancerPerformance statusClinical outcomes
2020
The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization.
Wong W, Sheinson D, Ogale S, Flores C, Gross C. The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization. Journal Of Clinical Oncology 2020, 38: 98-98. DOI: 10.1200/jco.2020.38.29_suppl.98.Peer-Reviewed Original ResearchMetastatic breast cancerMetastatic colorectal cancerAdvanced non-small cell lung cancerNational coverage decisionNGS testingUtilization trendsNext-generation sequencingNGS testsNon-small cell lung cancerCell lung cancerInterrupted time series analysisDe-identified databaseDiagnosis dateAdvanced melanomaPrimary cancerRetrospective studyColorectal cancerLung cancerInsurance typeCancer clinicMetastatic cancerBreast cancerUse of NGSTesting ratesCancer